hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06302062 id: FIT003-001 briefTitle: Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors acronym: TAL-T overallStatus: RECRUITING date: 2023-06-06 date: 2025-12-30 date: 2026-06-30 date: 2024-03-08 date: 2024-03-08 name: Guangzhou FineImmune Biotechnology Co., LTD. class: INDUSTRY briefSummary: A total of 17 to 23 participants are anticipated to be enrolled in the Phase I clinical trial, which is further divided into two distinct parts: one part involves single-agent cell therapy, while the other entails a combination of cell therapy and Serplulimab Injection.
To be more precise, the study aims to include patients who have been diagnosed with metastatic or locally advanced refractory/recurrent malignant solid tumors and have shown resistance to standard therapeutic interventions. These tumor types may encompass head and neck cancer, ovarian cancer, lung cancer, melanoma, and others. conditions: Advanced Solid Tumor conditions: Tumor Associated Lymph Node T Cell conditions: Immunotherapy studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 23 type: ESTIMATED name: Tumor Associated Lymph node T cell name: cyclophosphamide name: IL-2 name: Serplulimab Injection measure: DLT measure: MDT measure: Number of participants with treatment-related adverse events as assessed by CTCAE V4.03 measure: ORR measure: PFS measure: life quality score sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen University Cancer Center status: RECRUITING city: Guangzhou state: Gaungdong zip: 510700 country: China name: Xuzhi Pan role: CONTACT phone: 86-020-87343135 email: panxzh@sysucc.org.cn name: Xiaoshi Zhang, professor role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06302049 id: 12345 briefTitle: Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-05-01 date: 2026-05-01 date: 2024-03-08 date: 2024-03-08 name: Sadat City University class: OTHER briefSummary: The aim of the study is to test the implication of esomeprazole as a possible potential therapy for patients with NASH through evaluating its effect on ultrasound and fibrosis risk scores, serum levels of liver fibrosis biomarkers (fibronectin 1), insulin resistance, metabolic and inflammatory parameters. conditions: Fatty Liver Disease conditions: Steatohepatitis, Nonalcoholic studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 46 type: ESTIMATED name: Esomeprazole name: Placebo measure: Change in non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) measure: Liver function improvement measure: Reduction of oxidative stress sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06302036 id: 7777777 briefTitle: Emotional Freedom Techniques (EFT) on Stress, Anxiety and Depression in University Students Experiencing Earthquakes overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2024-04-05 date: 2024-04-28 date: 2024-03-08 date: 2024-03-08 name: Emine Yıldırım class: OTHER briefSummary: After two earthquakes in Kahramanmaraş Pazarcık in our country, the continuation of long-term aftershocks caused repetition of psychological problems and difficulties in recovery. Social and spiritual support plays a key role in the post-traumatic recovery period. It is necessary to use psychological support methods that can be applied in a short time and whose effect can be observed in a short time in the spiritual healing and healing of traumas. The emotional freedom technique (EFT) is One of the short-term psychotherapeutic techniques and ıt can also be applied online. EFT, which can be easily applied by individuals or professionals after receiving the necessary training; Cognitive therapy, acceptance and commitment therapy combine elements of acupuncture point stimulation, relying on manual stimulation of acupuncture points rather than using acupuncture needles. When we look at the literature, many scientific studies have been found in which the effectiveness of EFT on anxiety, stress and depression has been evaluated, but there has been no randomized controlled study evaluating the effectiveness of EFT online on individuals who have experienced earthquakes. With this project, it is aimed to determine the effect of online Emotional Freedom Techniques (EFT) on stress, anxiety and depression in university students who experienced earthquakes.
This study, which will be carried out as a randomized controlled experimental study, will be carried out between 16.12.2023 and 20.12.2023 by online with university students who score 17 or higher on the Beck Depression Scale. Total of 60 students with depressive symptoms will be recruited to the intervention and control groups, EFT sessions will be applied to the intervention group, and the control group will only be followed. At the beginning of the application, pre-tests (Information Form, Beck Depression Inventory, State Trait Anxiety Inventory, Perceived Stress Inventory) and at the end of the last session, post-tests will be applied for both groups.
With this study, a randomized controlled study will be brought to the literature on the effectiveness of a therapeutic method such as EFT, which is a method that can be used after an earthquake, which is easy to apply, has no cost, and can be accessed online in hard-to-reach areas. Our project will both contribute to the literature and provide short and long-term benefits in practice, in terms of raising awareness of students about important mental problems such as anxiety and depression, which are likely to be experienced after the earthquake, and enabling them to continue their education in a healthy way. It is aimed to present the work planned within the project as a paper in at least one national / international congress. It is aimed to publish in journals within the scope of SCI, SCI-Expanded related to the research area. The results and outputs of the research will be shared in various media (Kırklareli University and Osmaniye Korkut Ata University website and social media accounts).
By determining the stress, anxiety and depression status of university students who have experienced an earthquake, it will be possible to reduce their stress, anxiety and depression with EFT application. The fact that the application used is a short-term, effective and easy psychotherapy method will prevent the disruption of the normal education processes of the students. It will make an economic contribution by reducing the need for psychological drugs that may be needed to reduce the effects of the earthquake. conditions: Emotional Problem conditions: University Students Who Experienced an Earthquake studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: EFT will be applied and surveys will be administered to the intervention group. No application will be made to the control group and surveys will be asked. primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 30 type: ESTIMATED name: EFT measure: depression measure: stress, anxiety sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06302023 id: HE661462 briefTitle: Docosahexaenoic Acid (DHA) Supplementation During Pregnancy Reduces the Risk of Preterm Birth in Threatened Preterm Labor overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-05-31 date: 2025-05-31 date: 2024-03-08 date: 2024-03-08 name: Khon Kaen University class: OTHER briefSummary: The goal of this clinical trial is to learn about the effects of Docosahexaenoic acid (DHA) in reducing the incidence of premature birth in threatened preterm labor
* Group 2 (control) Participant will not need to take a DHA conditions: Pregnant Women Diagnosed With Threatened Preterm Labor studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Docosahexaenoic acid (DHA) 1000 mg measure: Number of Participants with preterm birth measure: Rate of low birth weight neonate measure: Rate of Neonatal Intensive care unit admission sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06302010 id: KafkasU3636 briefTitle: The Effect of Stress Ball Intervention During Non-Stress Test on Anxiety and Fetal Well-Being in High-Risk Pregnancy overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-08-31 date: 2024-08-31 date: 2024-03-08 date: 2024-03-08 name: Hümeyra TÜLEK DENİZ class: OTHER briefSummary: This research will be conducted to determine the effect of stress ball intervention during NST on anxiety and fetal well-being in high-risk pregnant women. Women with high-risk pregnancies randomly assigned to intervention (n=43) and control (n=43) groups at a state and a faculty hospital in Turkey will be included in the study. Pregnant women in the intervention group will be told to squeeze and release the ball once after counting to three, to inhale each time they press the ball, to exhale when they relax their grip and to focus only on the ball. Pregnant women will be instructed to continue this practice throughout the NST procedure (approximately 20 minutes). Pregnant women in the control group will not receive any intervention other than routine hospital care during the NST procedure. Data on anxiety and fetal well-being outcomes will be collected before and after NST. conditions: Anxiety conditions: Fetal Conditions conditions: Pregnancy Related studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The research will be conducted as a two-group, parallel, randomized, controlled experimental study with a pretest-posttest design. primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 86 type: ESTIMATED name: Stress Ball Intervention measure: Anxiety measure: Fetal well-being measure: Fetal well-being measure: Fetal well-being measure: Fetal well-being measure: Fetal well-being sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06301997 id: IRCT20210218050404N5 id: IR.FUMS.REC.1400.125 type: OTHER domain: Fasaums briefTitle: A Herbal Compound for Psoriasis overallStatus: ACTIVE_NOT_RECRUITING date: 2023-02-01 date: 2024-03-30 date: 2024-12-30 date: 2024-03-08 date: 2024-03-08 name: Fasa University of Medical Sciences class: OTHER name: Zarrin Avaye Kowsar Salamat (ZAX company) briefSummary: The goal of this interventional clinical trial study is to compare ZAX.1400.P03 and placebo in Psoriasis patients. The main question it aims to answer is:
Researchers will compare treatment and placebo groups to see if there is any improvement in the clinical signs of skin caused by psoriasis after treatment with ZAX.1400.P03 for 3 weeks. conditions: Psoriasis conditions: Inflammation conditions: Skin Diseases studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 104 type: ACTUAL name: ZAX.1400.P03 name: Placebo measure: Change from Baseline in Dermatology Life Quality Index (DLQI) score at Day0 (Baseline), Day7, Day14, Day21, Day28, Day35, and Day42 measure: Change From Baseline in Percent Body Surface Area (%BSA) at Day0 (Baseline), Day7, Day14, Day21, Day28, Day35, and Day42 measure: Change From Baseline in erythema score at Day0 (Baseline), Day7, Day14, Day21, Day28, Day35, and Day42 measure: Change From Baseline in Swelling score at Day0 (Baseline), Day7, Day14, Day21, Day28, Day35, and Day42 measure: Change From Baseline in pruritus score at Day0 (Baseline), Day7, Day14, Day21, Day28, Day35, and Day42 measure: Change From Baseline in flake score at Day0 (Baseline), Day7, Day14, Day21, Day28, Day35, and Day42 measure: Change From Baseline in skin dryness score at Day0 (Baseline), Day7, Day14, Day21, Day28, Day35, and Day42 measure: Change From Baseline in skin irritation score at Day0 (Baseline), Day7, Day14, Day21, Day28, Day35, and Day42 measure: Change From Baseline in pain score at Day0 (Baseline), Day7, Day14, Day21, Day28, Day35, and Day42 measure: Change From Baseline in skin scratch score at Day0 (Baseline), Day7, Day14, Day21, Day28, Day35, and Day42 measure: Change From Baseline in skin scar score at Day0 (Baseline), Day7, Day14, Day21, Day28, Day35, and Day42 measure: Change From Baseline in skin thickness score at Day0 (Baseline), Day7, Day14, Day21, Day28, Day35, and Day42 measure: Change From Baseline in skin rashes score at Day0 (Baseline), Day7, Day14, Day21, Day28, Day35, and Day42 sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Fasa university of medical sciences city: Fasa state: Fars zip: 7461686688 country: Iran, Islamic Republic of lat: 28.9383 lon: 53.6482 hasResults: False
nctId: NCT06301984 id: ANDROMEDA_01_2023_V1 briefTitle: Safety and Efficacy Evaluation of Insight GS Growing System overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2027-06 date: 2027-08 date: 2024-03-08 date: 2024-03-08 name: EVEREST PESQUISA E DESENVOLVIMENTO LTDA class: OTHER briefSummary: Premarket, interventional, single-arm clinical study, to evaluate the safety and efficacy of Insight GS Growing System in the surgical treatment of Early Onset Scoliosis (EOS). Also, to evaluate the difference in height of the spine and trunk, the success rate of the procedure, monitor adverse events and evaluate the satisfaction of the patient and care providers. The Andromeda Insight Growing System (Insight GS) is intended to treat severe, progressive multi-planar spinal deformities such as early-onset scoliosis while allowing for skeletal growth.
Patients will be screened in the outpatient setting of the study site. All participants who meet the eligibility criteria will be invited to participate in the study, which includes screening/pre-op, surgery to install the Insight GS system, and follow-up visits at 6 weeks, 2, 4, 6, 8, 10, 12,. 18 and 24 months for data collection, clinical evaluation, imaging, and monitoring of adverse events. conditions: Early Onset Scoliosis (EOS) studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 26 type: ESTIMATED name: Insight GS measure: Cobb Angle measure: Adverse event measure: Trunk height measure: Pain measure: Satisfaction sex: ALL minimumAge: 3 Years maximumAge: 10 Years stdAges: CHILD facility: Hospital Ortopédico AACD city: São Paulo state: SP zip: 04027-000 country: Brazil name: Mariana F Goncalves role: CONTACT email: mfgoncalves@aacd.org.br name: Alexandre F Cristante role: PRINCIPAL_INVESTIGATOR lat: -23.5475 lon: -46.63611 hasResults: False
nctId: NCT06301958 id: 202102567A3 briefTitle: Dextrose Prolotherapy on Articular Cartilage overallStatus: RECRUITING date: 2023-01-21 date: 2024-08-31 date: 2024-08-31 date: 2024-03-08 date: 2024-03-08 name: Chang Gung Memorial Hospital class: OTHER briefSummary: Dextrose prolotherapy is a controversial injection therapy in sports medicine. Currently, 25% hypertonic glucose solution is commonly used in clinical practice. Although this method has a certain therapeutic effect, there is still some controversy about the molecular mechanism of dextrose prolotherapy. In the past, it was thought that local stimulation would increase inflammatory reactions such as local leukocyte and macrophage infiltration and restart the "self-healing mechanism." However, some studies have pointed out that this treatment can cause cell apoptosis. In my clinical work, I often perform dextrose prolotherapy. I deeply feel the importance of exploring the detailed mechanism of action of this therapy in order to apply this therapy more appropriately to patients. We believe that the concentration of 25% hypertonic glucose solution should show a stepwise decrease in the joint cavity. Our preliminary cell experiment results using 2-fold serial dilutions of 25% glucose solution showed that 25%, 12% and 6% glucose solution will trigger the apoptosis of chondrocytes, vascular endothelial cells and immune cells, and will also inhibit the expression of the pro-inflammatory factor IL-6. Glucose solution below 3% will not have the effect of inducing apoptosis on cells. We believe that the therapeutic effect of 25% hypertonic glucose solution in the joint cavity may have cell-specific effects as the concentration changes dynamically. Therefore, in this study, we will clarify the therapeutic mechanism of dextrose prolotherapy for arthritis through basic research and clinical specimen analysis. The clinical research part will use clinical synovial fluid specimens to verify the therapeutic mechanism of hypertonic glucose dissolution. The joint pain level assessment of different types of patients (OA and RA) before dextrose prolotherapy (preliminary period), 1 month after treatment (midterm period) and 3 months after treatment (late period) will be collected, and joint effusion will be measured. Further analyze the cell apoptosis and concentration changes of inflammatory response factors in the liquid.
We hope that through this study, we will have a clear understanding of the molecular mechanism of dextrose prolotherapy on joint component cells. This result will have reference value for the more appropriate application of dextrose prolotherapy in the treatment of human cartilage-related lesions. conditions: Arthritis Knee studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 60 type: ESTIMATED name: Dextrose prolotherapy measure: Visual Analogue Scale (VAS) measure: Western Ontario and McMaster Universities Arthritis Index (WOMAC) measure: Interleukin 6 (IL-6) sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chang Gung Memorial Hospital, Chiayi status: RECRUITING city: Chiayi City state: 嘉義市 zip: 600 country: Taiwan name: HUNG-CHIH HSU, PhD role: CONTACT phone: +886-3-3621000 phoneExt: 2601 email: dr.tonyhsu@gmail.com lat: 23.47917 lon: 120.44889 hasResults: False
nctId: NCT06301945 id: Maastro Clinic id: 72725524 type: OTHER_GRANT domain: Hanarth Fonds briefTitle: Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors acronym: INTHYM overallStatus: RECRUITING date: 2023-08-01 date: 2027-08-01 date: 2027-08-01 date: 2024-03-08 date: 2024-03-27 name: Erasmus Medical Center class: OTHER name: Maastro Clinic, The Netherlands name: Hospices Civils de Lyon briefSummary: Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and/or more aggressive subtypes, defined by the WHO histopathological classification.
The ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy. conditions: Thymic Epithelial Tumor conditions: Thymic Carcinoma conditions: Thymoma conditions: Thymoma and Thymic Carcinoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1020 type: ESTIMATED name: Artificial Intelligence Diagnostics name: Recurrence Prediction Tool measure: WP1 - Databases/Data Pre-processing measure: WP2 - Deep Learning-Model for TET Classification and Recurrence Prediction measure: WP3: Clinical Evaluation sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus MC status: RECRUITING city: Rotterdam state: South Holland zip: 3015 GD country: Netherlands name: Anna Salut Esteve Domínguez role: CONTACT email: a.estevedominguez@erasmusmc.nl lat: 51.9225 lon: 4.47917 hasResults: False
nctId: NCT06301932 id: ANE-2562-06771 briefTitle: The Effectiveness and Outcomes of Epidural Analgesia in Patients Undergoing Open Hepatectomy overallStatus: COMPLETED date: 2006-01-01 date: 2018-12-31 date: 2023-12-31 date: 2024-03-08 date: 2024-03-12 name: Chiang Mai University class: OTHER briefSummary: This observational study is to compare the effectiveness and outcomes of epidural analgesia in patients undergoing open hepatectomy: A propensity score matching analysis.
The main question is: What is the superior method of pain control in open hepatectomy: epidural analgesia or intravenous PCA? conditions: Epidural Analgesia conditions: Patient Controlled Analgesia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 654 type: ACTUAL name: Open liver resection measure: Post-operative opioid consumption sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06301919 id: IRBN042024/CHUSTE briefTitle: Use of N-Butyl Cyanoacrylate in Transarterial Emergency Embolization overallStatus: RECRUITING date: 2024-03-01 date: 2024-05-01 date: 2024-05-01 date: 2024-03-08 date: 2024-03-12 name: Centre Hospitalier Universitaire de Saint Etienne class: OTHER briefSummary: NBCA is a synthetic biodegradable cyanoacrylate basis glue, modified by the addition of a monomer with adhesive, hemostatic, and antiseptic properties.
The aim of this retrospective monocentric study was to evaluate safety and efficacy of use of NBCA as embolic agent in emergency setting. conditions: Haemostasis Embolisation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 100 type: ESTIMATED name: Clinical data name: Imaging data name: Biological data measure: Evaluation of technical success measure: Assessment of clinical success measure: Assessment of clinical success measure: Assessment of clinical success measure: Assessment of clinical success measure: Assessment of clinical success sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU de Saint-Etienne status: RECRUITING city: Saint-Priest-en-Jarez zip: 42270 country: France name: Rémi Grange, MD role: CONTACT phone: (0)477828963 phoneExt: +33 email: remi.grange@chu-st-etienne.fr name: Sylvain Grange, MD role: SUB_INVESTIGATOR name: Rémi Grange, MD role: PRINCIPAL_INVESTIGATOR lat: 45.47501 lon: 4.37614 hasResults: False